Amgen Inc. (NASDAQ:AMGN) Shares Sold by JT Stratford LLC

JT Stratford LLC cut its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 52.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,110 shares of the medical research company's stock after selling 1,223 shares during the period. JT Stratford LLC's holdings in Amgen were worth $289,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Cornerstone Advisory LLC grew its holdings in shares of Amgen by 3.7% during the fourth quarter. Cornerstone Advisory LLC now owns 2,584 shares of the medical research company's stock worth $673,000 after buying an additional 92 shares in the last quarter. Mosaic Family Wealth Partners LLC grew its position in Amgen by 28.2% during the 4th quarter. Mosaic Family Wealth Partners LLC now owns 1,846 shares of the medical research company's stock worth $481,000 after purchasing an additional 406 shares during the last quarter. RB Capital Management LLC raised its stake in Amgen by 2.7% during the 4th quarter. RB Capital Management LLC now owns 15,093 shares of the medical research company's stock valued at $3,934,000 after acquiring an additional 401 shares during the last quarter. Pinkerton Retirement Specialists LLC raised its stake in shares of Amgen by 6.1% during the fourth quarter. Pinkerton Retirement Specialists LLC now owns 14,727 shares of the medical research company's stock worth $3,839,000 after purchasing an additional 846 shares during the last quarter. Finally, Poehling Capital Management INC. boosted its holdings in shares of Amgen by 59.8% in the fourth quarter. Poehling Capital Management INC. now owns 1,539 shares of the medical research company's stock valued at $401,000 after acquiring an additional 576 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Guggenheim initiated coverage on Amgen in a research report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price target on the stock. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Royal Bank of Canada cut their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Finally, Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Amgen has a consensus rating of "Hold" and a consensus price target of $309.22.

Amgen Trading Down 0.0%

NASDAQ:AMGN traded down $0.03 during trading hours on Wednesday, reaching $279.43. 699,438 shares of the stock were exchanged, compared to its average volume of 2,788,962. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $150.25 billion, a price-to-earnings ratio of 37.08, a PEG ratio of 2.63 and a beta of 0.51. The business has a 50-day moving average of $285.23 and a two-hundred day moving average of $285.81. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. During the same period in the prior year, the firm posted $3.96 EPS. The business's quarterly revenue was up 9.4% compared to the same quarter last year. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.41%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is 86.86%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.